Company: CRNX
Filing Date: 2025-04-23
Form Type: DEF 14A
Source: 0000950170-25-057452
Chunk: 72

Company: Crinetics Pharmaceuticals, Inc.
Filing Date: 2025-04-23
Form: DEF 14A
Chunk 72
---
 in which they were employed by us. For purposes of the table above, such amounts represent their 2024 annual incentive award. All cash severance payments are paid in a lump sum.

The value attributable to the accelerated options represents the excess of the fair market value of our common stock of $51.13 on December 31, 2024, over the exercise price of the unvested options the vesting of which accelerates in connection with the applicable triggering event. In the event of an involuntary termination without cause or resignation for good reason apart from a CIC and death/disability, shares subject to acceleration represent the vesting and exercisability of outstanding unvested options as to the number of options that would have vested over the applicable severance period had such officer remained continuously employed by us during such period. In the event of a change in control, an executive’s equity awards will vest upon the earliest of (a) the executive’s termination without cause or resignation for good reason or (b) the first anniversary of the change in control. The change in control values above reflect the value of the accelerated vesting of all outstanding equity awards held by the executive officer as of December 31, 2024, since such awards would vest on the first anniversary of the closing of the change in control absent an earlier involuntary termination.

Represents the aggregate value of the accelerated vesting of RSU awards, calculated by multiplying the fair market value of our common stock of $51.13 on December 31, 2024, by the number of RSUs the vesting of which accelerates in connection with the applicable triggering event. In the event of an involuntary termination without cause or resignation for good reason apart from a CIC and death/disability, shares subject to acceleration represent the vesting and exercisability of outstanding unvested RSUs as to the number of RSUs that would have vested over the applicable severance period had such officer remained continuously employed by us during such period. In the event of a change in control, an executive’s equity awards will vest upon the earliest of (a) the executive’s termination without cause or resignation for good reason or (b) the first anniversary of the change in control. The change in control values above reflect the value of the accelerated vesting of all outstanding equity awards held by the executive officer as of December 31, 2024, since such awards would vest on the first anniversary of the closing of the change in control absent an earlier involuntary termination.

Represents the value of